ProCE Banner Activity

A Walk in the PARP: Remodeling the Landscape of Newly Diagnosed Advanced Ovarian Cancer (With German Subtitles)

Multimedia
Watch this on-demand webcast capturing a live CCO webinar featuring expert presentations on the latest data on PARP inhibitors and how to integrate them into your clinical practice for optimal treatment of patients with newly diagnosed advanced ovarian cancer. Features German subtitles!

Released: April 26, 2021

Expiration: April 25, 2022

Share

Faculty

Alexandra Leary

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab
Institut Gustave Roussy
Paris, France

Prof Jonathan A. Ledermann

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci

Professor of Medical Oncology
CRUK and UCL Cancer Trials Centre
UCL Cancer Institute
Honorary Consultant in Medical Oncology
Cancer Services
UCL Hospitals
London, United Kingdom

Frederik Marmé

Frederik Marmé, MD, PhD

Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg
Heidelberg, Germany

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Learning Objectives

  • Assess recent clinical data on the safety and efficacy of PARP inhibitors for the frontline treatment of ovarian cancer
  • Recognize PARP inhibitor–related toxicities and define supportive management strategies to minimize these adverse events
  • Discuss ongoing clinical research evaluating the role of PARP inhibitors in combination with chemotherapy, targeted therapy, and immunotherapy as frontline therapy for ovarian cancer to aid referral for clinical trial participation

Program Director Disclosure

Program Director

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci

Professor of Medical Oncology
CRUK and UCL Cancer Trials Centre
UCL Cancer Institute
Honorary Consultant in Medical Oncology
Cancer Services
UCL Hospitals
London, United Kingdom

Prof Jonathan A. Ledermann, MD, FRCPO, FMed Sci, has disclosed that he has received consulting fees from AstraZeneca, Artios, Clovis Oncology, Eisai, GlaxoSmithKline, MSD/Merck, Pfizer, and Regeneron and other financial or material support from AstraZeneca and MSD/Merck.

Faculty Disclosure

Primary Author

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab
Institut Gustave Roussy
Paris, France

Alexandra Leary, MD, PhD, has disclosed that she has received research contracts from AstraZeneca.

Frederik Marmé, MD, PhD

Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg
Heidelberg, Germany

Prof. Dr. med. Frederik Marmé has disclosed that he has received consulting fees from Amgen, AstraZeneca, Celgene, Clovis, CureVac, Eisai, Genomic Health, Immunomedics, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Tesaro, and Vaccibody.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.